{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T01:44:48Z","timestamp":1789868688033,"version":"4.0.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"European Alliance of Associations for Rheumatology"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1136\/ard-2022-223628","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T09:00:14Z","timestamp":1678266014000},"page":"754-762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-5102","authenticated-orcid":false,"given":"Javier","family":"Rodr\u00edguez-Carrio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Burska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-5665","authenticated-orcid":false,"given":"Philip G","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem A","family":"Dik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-7832","authenticated-orcid":false,"given":"Robert","family":"Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija-Leena","family":"Eloranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-4671","authenticated-orcid":false,"given":"Dimitrios T","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0915-7245","authenticated-orcid":false,"given":"Marie","family":"Wahren-Herlenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rehwinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2798-9141","authenticated-orcid":false,"given":"Marie-Louise","family":"Fr\u00e9mond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-2020","authenticated-orcid":false,"given":"Mary K","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9403-6503","authenticated-orcid":false,"given":"Lars","family":"R\u00f6nnblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-5386","authenticated-orcid":false,"given":"Marjan A","family":"Versnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-4755","authenticated-orcid":false,"given":"Edward M","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223628_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ard-2022-223628_bib2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-223628_bib3","first-page":"1662","article-title":"Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy","volume":"56","author":"Psarras","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1136\/ard-2022-223628_bib4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar2886","article-title":"Type I interferon in organ-targeted autoimmune and inflammatory diseases","volume":"12","author":"Crow","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223628_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223628_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40291-019-00433-x","article-title":"FebriDx\u00ae: A rapid diagnostic test for differentiating bacterial and viral aetiologies in acute respiratory infections","volume":"23","author":"Shirley","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"10.1136\/ard-2022-223628_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002876","article-title":"Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider","author":"Burska","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223628_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002864","article-title":"Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR pointspoints to considerconsider","author":"Rodr\u00edguez-Carrio","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223628_bib10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: what do they all do?","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu Rev Virol"},{"key":"10.1136\/ard-2022-223628_bib11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2022-223628_bib12","first-page":"1077","article-title":"Methods for type I interferon detection and their relevance for clinical utility and improved understanding of rheumatic diseases","volume":"37","author":"Lamot","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223628_bib13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/BOR.0b013e32835c7e32","article-title":"The interferon signature in autoimmune diseases","volume":"25","author":"R\u00f6nnblom","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard-2022-223628_bib15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","article-title":"Type I interferons in autoimmune disease","volume":"14","author":"Crow","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"10.1136\/ard-2022-223628_bib16","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1093\/rheumatology\/keac083","article-title":"Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study","volume":"61","author":"Wahadat","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223628_bib17","doi-asserted-by":"crossref","first-page":"e37000","DOI":"10.1371\/journal.pone.0037000","article-title":"Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients","volume":"7","author":"Somers","year":"2012","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-223628_bib18","doi-asserted-by":"crossref","first-page":"e24828","DOI":"10.1371\/journal.pone.0024828","article-title":"Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis","volume":"6","author":"Reynier","year":"2011","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-223628_bib19","doi-asserted-by":"crossref","first-page":"A72","DOI":"10.1136\/annrheumdis-2016-209124.171","article-title":"A9.05\u2005distinct subsets of interferon-stimulated genes are associated with incomplete and established systemic lupus erythematosus","volume":"75","author":"Psarras","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib20","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1038\/s41598-018-24198-1","article-title":"A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features","volume":"8","author":"El-Sherbiny","year":"2018","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2022-223628_bib21","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2022-223628_bib22","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1002\/art.24803","article-title":"Interferon-Regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study","volume":"60","author":"Bauer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib23","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard-2022-223628_bib24","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1371\/journal.pmed.0030491","article-title":"Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus","volume":"3","author":"Bauer","year":"2006","journal-title":"PLoS Med"},{"key":"10.1136\/ard-2022-223628_bib25","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib26","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","article-title":"Type I interferon system activation and association with disease manifestations in systemic sclerosis","volume":"69","author":"Eloranta","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.37742","article-title":"Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib28","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kei244","article-title":"Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients","volume":"45","author":"Tan","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223628_bib29","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib30","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/eji.200738008","article-title":"Systemic increase in type I interferon activity in Sj\u00f6gren's syndrome: a putative role for plasmacytoid dendritic cells","volume":"38","author":"Wildenberg","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1136\/ard-2022-223628_bib31","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib32","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/annrheumdis-2012-202552","article-title":"Mxa as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome","volume":"73","author":"Maria","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/rheumatology\/kex490","article-title":"Systemic interferon type I and type II signatures in primary Sj\u00f6gren's syndrome reveal differences in biological disease activity","volume":"57","author":"Bodewes","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223628_bib34","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.3389\/fimmu.2017.02007","article-title":"Heterogeneity of the type I interferon signature in rheumatoid arthritis: a potential limitation for its use as a clinical biomarker","volume":"8","author":"Rodr\u00edguez-Carrio","year":"2017","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2022-223628_bib35","doi-asserted-by":"crossref","first-page":"e86069","DOI":"10.1371\/journal.pone.0086069","article-title":"IFN\u03b1 serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients","volume":"9","author":"Rodr\u00edguez-Carrio","year":"2014","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-223628_bib36","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/ard.2006.063412","article-title":"Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients","volume":"66","author":"van der Pouw Kraan","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib37","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1136\/annrheumdis-2016-209124.13","article-title":"A1.13\u2005the prevalence of a raised interferon gene signature is increased in early RA and is associated with worse disease activity","volume":"75","author":"Cooles","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib38","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon \u03b2 is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib39","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"key":"10.1136\/ard-2022-223628_bib41","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/art.27224","article-title":"Systemic sclerosis and lupus: points in an interferon-mediated continuum","volume":"62","author":"Assassi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib43","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/art.23404","article-title":"Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus","volume":"58","author":"Biesen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib44","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaci.2017.08.026","article-title":"The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy","volume":"141","author":"Cooles","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2022-223628_bib45","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/gene.2008.98","article-title":"Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers","volume":"10","author":"Bos","year":"2009","journal-title":"Genes Immun"},{"key":"10.1136\/ard-2022-223628_bib46","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3899\/jrheum.080418","article-title":"Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis","volume":"35","author":"Air\u00f2","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223628_bib47","doi-asserted-by":"crossref","first-page":"e000080","DOI":"10.1136\/lupus-2014-000080","article-title":"Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE","volume":"2","author":"Kennedy","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-223628_bib48","author":"Dutton"},{"key":"10.1136\/ard-2022-223628_bib49","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223628_bib50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A phase II study of the efficacy and safety of rontalizumab (rhumab interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib51","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223628_bib52","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib53","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/annrheumdis-2012-201586","article-title":"Ifn\u03b1 and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus","volume":"72","author":"Rose","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"10.1136\/ard-2022-223628_bib55","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2022-223628_bib56","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital enzyme-linked immunosorbent assay quantification of serum interferon-\u03b1","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223628_bib57","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/rheumatology\/kex220","article-title":"Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study","volume":"56","author":"Rose","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223628_bib58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaut.2016.12.005","article-title":"Pathways of impending disease flare in african-american systemic lupus erythematosus patients","volume":"78","author":"Munroe","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2022-223628_bib59","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/annrheumdis-2018-213386","article-title":"Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status","volume":"77","author":"Md Yusof","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib60","doi-asserted-by":"crossref","first-page":"e000159","DOI":"10.1136\/lupus-2016-000159","article-title":"Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection","volume":"3","author":"Mackay","year":"2016","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-223628_bib61","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar2912","article-title":"Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment","volume":"12","author":"van Baarsen","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223628_bib62","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/annrheumdis-2012-202753","article-title":"The type I IFN signature as a biomarker of preclinical rheumatoid arthritis","volume":"72","author":"L\u00fcbbers","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib63","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib64","doi-asserted-by":"crossref","first-page":"e000284","DOI":"10.1136\/lupus-2018-000284","article-title":"Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-223628_bib65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/keu299","article-title":"Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to tnfi therapy","volume":"54","author":"Wright","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223628_bib66","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/art.27226","article-title":"Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta\/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort","volume":"62","author":"Mavragani","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib67","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2015-208001","article-title":"Increased pretreatment serum IFN-\u03b2\/\u03b1 ratio predicts non-response to tumour necrosis factor \u03b1 inhibition in rheumatoid arthritis","volume":"75","author":"Wampler Muskardin","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib68","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/art.38400","article-title":"Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray","volume":"66","author":"Sanayama","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223628_bib69","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1002\/art.27702","article-title":"Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients","volume":"62","author":"Thurlings","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib70","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/ard.2010.147199","article-title":"Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis","volume":"70","author":"Vosslamber","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib71","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3819","article-title":"The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients","volume":"14","author":"Raterman","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223628_bib72","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13075-015-0564-y","article-title":"Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab","volume":"17","author":"de Jong","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223628_bib73","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.37785","article-title":"Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon \u03b1-kinoid","volume":"65","author":"Lauwerys","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib74","doi-asserted-by":"crossref","first-page":"e000286","DOI":"10.1136\/lupus-2018-000286","article-title":"Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE","volume":"5","author":"Casey","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-223628_bib75","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1002\/art.23035","article-title":"Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus","volume":"56","author":"Lee","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223628_bib76","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2022-223628_bib77","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib78","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar3017","article-title":"Monocyte surface expression of fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus","volume":"12","author":"Li","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223628_bib79","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1177\/0961203311409963","article-title":"Possible role of the JAK\/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus","volume":"20","author":"Kawasaki","year":"2011","journal-title":"Lupus"},{"key":"10.1136\/ard-2022-223628_bib80","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/107999099313901","article-title":"Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta","volume":"19","author":"Jabs","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1136\/ard-2022-223628_bib81","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun"},{"key":"10.1136\/ard-2022-223628_bib82","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1093\/rheumatology\/keab875","article-title":"Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus","volume":"61","author":"Zorn-Pauly","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223628_bib83","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/annrheumdis-2021-221835","article-title":"Serum interferon-\u03b1 levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity","volume":"81","author":"Chasset","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223628_bib84","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/rheumatology\/keab688","article-title":"Serum interferon-\u03b12 measured by single-molecule array associates with systemic disease manifestations in Sj\u00f6gren's syndrome","volume":"61","author":"Huijser","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223628_bib85","first-page":"e75","article-title":"Reframing immune-mediated inflammatory diseases","volume":"385","author":"Boutrid","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223628_bib86","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10875-020-00952-x","article-title":"Differential expression of interferon-alpha protein provides clues to tissue specificity across type I interferonopathies","volume":"41","author":"Lodi","year":"2021","journal-title":"Journal of Clinical Immunology"},{"key":"10.1136\/ard-2022-223628_bib87","doi-asserted-by":"crossref","first-page":"e001934","DOI":"10.1136\/rmdopen-2021-001934","article-title":"SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies","volume":"8","author":"Graf","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223628_bib88","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3390\/ph15101198","article-title":"SIGLEC-1 in systemic sclerosis: A useful biomarker for differential diagnosis","volume":"15","author":"H\u00f6ppner","year":"2022","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1136\/ard-2022-223628_bib89","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1038\/s41598-020-60563-9","article-title":"Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus","volume":"10","author":"Smith","year":"2020","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2022-223628_bib90","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/art.42265","article-title":"Variability of primary sj\u00f6gren's syndrome is driven by interferon-\u03b1 and interferon-\u03b1 blood levels are associated with the class II HLA-DQ locus","volume":"74","author":"Trutschel","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T05:23:41Z","timestamp":1749792221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724083882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0003496724083882"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223628","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}